Overview 

Carnosinemia is a rare autosomal recessive metabolic disorder caused by a deficiency of the enzyme carnosinase. This condition leads to the accumulation of carnosine, a dipeptide made of β-alanine and histidine, in the blood, cerebrospinal fluid, and urine.¹ While carnosine plays a role in muscle pathology and antioxidation, its excess, due to enzyme deficiency, can affect neurological development.  

To understand why carnosinemia arises and how it is inherited, it's essential to explore the autosomal recessive inheritance pattern, the function of the CNDP1 gene, and how genetic mutations impact enzyme production. This article provides an in-depth look at these aspects, alongside implications for carriers, family planning, diagnosis, and genetic counselling. 

What is carnosinemia?

Biochemical basis

Carnosinemia is caused by a deficiency of serum carnosinase, an enzyme responsible for breaking down carnosine. The enzyme is encoded by the CNDP1 gene on chromosome 18q22.3.²

Carnosine is normally degraded after serving its role as an antioxidant and pH buffer, particularly in muscle and brain tissues. When carnosinase is absent or dysfunctional, carnosine builds up, leading to a range of symptoms.

Clinical presentation

Although some individuals may remain asymptomatic, classic infantile carnosinemia typically presents with:

• Developmental delay
• Intellectual disability 
• Hypotonia 
• Seizures
• Autistic behaviours
• Occasionally, a musty body odour due to carnosine accumulation

Inheritance pattern of carnosinemia: autosomal recessive

What does “autosomal recessive” mean?

In autosomal recessive disorders like carnosinemia:

• A person must inherit two copies of the mutated gene (one from each parent) to be affected
• Individuals with one normal copy and one mutated copy are called carriers and typically show no symptoms
• If both parents are carriers, there is:
  • 25% (1 in 4) chance the child will inherit both defective genes and have carnosinemia
  • 50% (1 in 2) chance the child will be a carrier
  • 25% (1 in 4) chance the child will inherit two normal genes

Autosomal recessive inheritance table

The inheritance pattern affects males and females equally, as the CNDP1 gene is on an autosome (non-sex chromosome).

The CNDP1 gene and its role

Function

• CNDP2 encodes serum carnosinase, an enzyme that hydrolyses carnosine and homocarnosine into histidine and β-alanine⁴.
• High activity of carnosine is typically found in adults; newborns have low levels that gradually rise with age.

Mutations

• Mutations in CNDP1 can cause loss of function or complete absence of the enzyme.
• Variants may include:
  • Missense mutations - changing one amino acid
  • Nonsense mutation - introducing a premature stop codon
  • Frameshift mutations, or 
  • Splicing error

In carnosinemia, these mutations prevent the enzyme from adequately metabolising carnosine, leading to accumulation.

Carrier state and its implications

Who is a carrier?

A carrier has one normal CNDP1 gene and one mutated gene⁵. Carriers are typically asymptomatic because one functional gene can produce enough enzyme.

How is carrier status detected?

• Genetic testing via sequencing of the CNDP1 gene
• Carrier screening is particularly recommended:
  • For parents of a child with carnosinemia
  • When there's a known family history
  • For couples from regions or populations with higher consanguinity

Can two carriers have an affected child?

Yes, if both parents are carriers, each pregnancy carries a 25% risk of producing a child with carnosinemia.

How carnosinemia is diagnosed

Newborn screening

Carnosinemia is not typically induced in standard newborn screening panels due to its rarity, but:

• Tandem mass spectrometry may occasionally detect elevated carnosine levels
• More often, a diagnosis is made after clinical symptoms appear

Laboratory diagnosis

• Urine and blood tests: Elevated carnosine levels in plasma and urine
• Enzyme activity assays: Confirm carnosinase deficiency
• Genetic testing: Confirms mutations in the CNDP1 gene

Prenatal and preimplantation genetic diagnosis

For at-risk couples (both carriers), options include:

1. Prenatal Diagnosis
   • Via chorionic villus sampling (CVS) or amniocentesis to test fetal DNA
   • Useful to determine whether the fetus is affected, a carrier, or unaffected
2. Preimplantation Genetic Diagnosis (PGD)
   • Used in vitro fertilisation (IVF)
   • Embryos are tested for CNDP1 mutations before implantation
   • Only unaffected embryos are selected for transfer

Management and prognosis

There is no definitive cure for carnosinemia. Management focuses on:

• Symptomatic support (e.g., physical therapy, seizure control)
• Monitoring developmental progress
• Nutritional interventions may be considered, through restricted histidine diets are largely unproven.

Prognosis varies:

• Asymptomatic adults with isolated biochemical elevations may live normal lives.
• Infantile-onset carnosinemia often results in significant developmental delay and seizure disorders.

Genetic counselling for families

Who should seek counselling?

• Parents of an affected child.
• Siblings and extended family members considering children.
• Carriers identified through genetic testing.

Counselling includes

• Risk estimation for current or future pregnancies.
• Discussion of reproductive options (e.g., IVF + PGD).
• Information about available testing for relatives.

Genetic counselling helps families make informed decisions and supports emotional adjustment to diagnosis.

FAQs

Is carnosinemia inherited from one or both parents?

Carnosinemia is inherited in an autosomal recessive pattern, meaning the affected child receives one mutated gene from each parent.

What are the chances that two carrier parents will have an affected child?

There is a 25% chance with each pregnancy that the child will inherit two mutated CNDP1 genes and have carnosinemia.

Can a carrier show symptoms of carnosinemia?

Typically no. Carriers usually have enough carnosinase activity from the one normal gene to prevent symptoms.

How do I know if I’m a carrier?

Genetic testing of the CNDP1 gene can confirm carrier status. This may be offered if there's a family history or known case in the family.

Is there a cure for carnosinemia?

No cure exists, but symptom management and supportive care can improve quality of life. Early diagnosis is important.

Are both males and females equally affected?

Yes. Since the CNDP1 gene is located on an autosome (non-sex chromosome), both sexes are equally affected.

Summary

Carnosinemia is a rare genetic disorder caused by a deficiency in carnosinase, resulting from mutations in the CNDP1 gene. The condition is inherited in an autosomal recessive pattern, where both parents must be carriers for a child to be affected.

Affected individuals, especially in infancy, may present with developmental delays, hypotonia, and seizures. Carrier testing and genetic counselling play critical roles in managing family risk. Though no cure exists, symptomatic treatment and early diagnosis can improve outcomes.

Understanding autosomal recessive inheritance empowers individuals and families to make informed decisions regarding health, reproduction, and genetic testing.